Meeting
2022 ASCO Gastrointestinal Cancers Symposium
Multicenter phase Ib/II study of second-line trastuzumab, ramucirumab, and paclitaxel in patients with HER2-positive advanced gastric or gastroesophageal junction cancer: Updated HER-RAM study with biomarker analysis.
Authors
Sun Young Rha
Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea
Sun Young Rha , Chang Gon Kim , Minkyu Jung , Hyo Song Kim , Choong-kun Lee , Hei-Cheul Jeung , Dong-Hoe Koo , Woo Kyun Bae , Dae Young Zang , Hyunki Kim , Hyun Cheol Cheol Chung
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT04888663
DOI
10.1200/JCO.2022.40.4_suppl.330
Abstract #
330
Poster Bd #
K8
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Multicenter phase Ib/II study of second-line trastuzumab, ramucirumab, and paclitaxel in patients with HER2-positive advanced gastric or gastroesophageal junction cancer (HER-RAM study).
First Author: Sun Young Rha
Poster
2013 Gastrointestinal Cancers Symposium
Significance of accurate HER2 testing as a new biomarker in advanced gastric cancer.
First Author: Tetsuya Kusumoto
Poster
2023 ASCO Gastrointestinal Cancers Symposium
nextHERIZON: A phase 2 study of HER-Vaxx, a HER2-targeting peptide vaccine, in combination with chemotherapy or pembrolizumab in patients with HER2 metastatic or advanced gastric/gastroesophageal adenocarcinoma that progressed on or after trastuzumab treatment.
First Author: Timothy Jay Price